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ease, hemodialysis treatment, dialyzer membrane material, car-N-terminal fragments of the proatrial natriuretic peptide in
diac dysfunction, and hypertension. Therefore, these are notpatients before and after hemodialysis treatment.
useful markers to accurately estimate volume status in hemodi-Background. Fragments derived from the prohormone of
alysis patients.a-human atrial natriuretic peptide (a-ANP) in patients with
cardiac failure are more closely related to the disease state
than intact a-ANP.
Methods. Specific immunoassays have been developed to Natriuretic peptides constitute a growing family ofdetect proANP 1-30, proANP 31-67, and proANP 1-98. Plasma
structurally related but genetically distinct natriureticconcentrations of these fragments were determined in 122 he-
peptides that regulate cardiorenal function [1–3]. Themodialysis patients with and without cardiac dysfunction, with
and without hypertension, as well as with and without dialysis- circulating hormones are involved in volume homeosta-
associated hypotensive episodes either before or after a regu- sis, blood pressure control, and electrolyte balance.
larly scheduled hemodialysis session. The effects of different Atrial natriuretic peptide (a-ANP) is a cardiac hormonedialyzer membranes were also evaluated. The results of these
stored as a 126-amino acid prohormone (proANP 1-126)assays along with other markers of volume regulation such as
within atrial granules [4]. In response to atrial wall ten-a-ANP and cyclic 39,59 guanosine monophosphate (cGMP)
were compared with those of healthy controls. sion [5], the prohormone is cleaved by a membrane pro-
Results. Predialytic and postdialytic plasma concentrations tease and is released into the circulation as a C-terminal
of the proANP fragments were markedly higher in uremic peptide [6], the active a-human ANP (proANP 99-126),patients than in controls (98-fold for proANP 1-98, 56-fold for
and a complementary N-terminal peptide, most likelyproANP 31-67, and 35-fold for proANP 1-30). All proANP
proANP 1-98 [7]. a-ANP regulates diuresis and natriure-fragments, a-ANP, and cGMP decreased during hemodialysis.
A strong linear correlation was found between predialytic and sis through specific renal receptors by activation of the
postdialytic plasma levels. There was no correlation, however, guanylate cyclase/cyclic 39,59 guanosine monophosphate
with the amount of fluid removed during hemodialysis. Patients
(cGMP) system [8]. It has been found that other frag-with altered left ventricular hemodynamics displayed signifi-
ments derived from the prohormone (N-terminal pro-cantly higher plasma concentrations of all proANP fragments
and a-ANP, but not cGMP, than patients with normal cardiac ANP 1-30, 31-67, and 79-98) are also present in the circu-
function. Hemodialysis patients with moderate or severe hyper- lation [9]. It has been further demonstrated that the
tension had higher concentrations of proANP fragments, fragments have biological function based on their ability
a-ANP, and cGMP than patients with normal blood pressure or
to increase renal guanylate cyclase activity [10] and topatients with only mild hypertension. There was no significant
vasodilate the aorta [11].difference in circulating levels of proANP peptides, a-ANP,
and cGMP between patients with and without frequent dialysis- a-Atrial natriuretic peptide is rapidly degraded, pri-
associated hypotensive episodes. Cellulose-triacetate dialyzers marily by the kidney, but also by other organs, with a
reduced plasma levels of proANP 1-30, proANP 31-67, and plasma half-life of two to four minutes. Pulsatile secre-proANP 1-98 significantly more than polysulfone dialyzers, but
tion into the circulation and methodical difficultiesa-ANP and cGMP levels were not different.
caused by instability of the peptide are also limiting fac-Conclusions. Circulating a-ANP and proANP fragments are
influenced by a variety of factors such as end-stage renal dis- tors for a precise determination of a-ANP. cGMP is
generated when a-ANP activates membrane-bound gua-
nylate cyclase. Because cGMP is more stable in plasmaKey words: atrial natriuretic peptide, cyclic GMP, end-stage renal dis-
ease, cardiac disease, blood pressure control. than a-ANP and because the radioimmunoassay (RIA)
for cGMP is somewhat less arduous, it was believed thatReceived for publication July 13, 1999
cGMP would potentially be a better marker for a-ANPand in revised form January 18, 2000
Accepted for publication February 2, 2000 activity. However, cGMP acts as second messenger for
several natriuretic peptides, and thus, specificity is low.Ó 2000 by the International Society of Nephrology
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In 1991, Winters and Vesely published data on plasma overload or underhydration, were investigated. Finally,
concentrations of proANP fragments in patients with the effects of different dialyzer membranes on the pro-
chronic renal failure and hemodialysis treatment [12]. ANP fragments were evaluated.
They have demonstrated that the C-terminus (that is,
active a-ANP) decreased during the hemodialysis ses-
METHODSsion, whereas N-terminal fragments (that is, proANP
Patients1-98 and proANP 31-67) increased. However, the
authors investigated only 13 patients. After successful We studied 122 regular hemodialysis patients, 55
kidney transplantation, a normalization of elevated cir- women and 67 men, with end-stage renal failure caused
culating N-terminal and C-terminal ANP prohormone by various underlying diseases. The age of the patients
concentrations was reported [13]. No data are available ranged from 21 to 86 years, with a mean (6 SD) age
on N-terminal proANP 1-30 or 79-98 in renal failure of 54 6 16 years. Patients with altered left ventricular
patients. Furthermore, the decrease of the ANP C-termi- hemodynamics (N 5 31), such as congestive heart failure,
nus and the increase of the ANP N-terminus observed cardiomyopathy, moderate to severe valve dysfunction,
during hemodialysis in the study of Winters and Vesely or atrial fibrillation, were also investigated. The patients
are difficult to explain [12]. were subjected to hemodialysis for 9 to 15 h/week. One
In nonuremic patients, the significance of circulating hundred and seven patients were treated with high-flux
proANP fragments has been increasingly investigated cellulose-triacetate (N210; Nipro, Osaka, Japan) or pol-
during the last years. It has been found that the N-ter- ysulfone dialyzers (F60 and F60S; Fresenius, Oberursel,
minal fragment proANP 1-98 significantly correlated Germany). Fifteen patients were dialyzed with low-flux
with echocardiographic measurements of left ventricular cellulose-triacetate (N120 and N150; Nipro). Blood flow
structure and performance, function of aortic and mitral was usually between 250 and 350 mL/min with a constant
valves. A correlation was also found between proANP dialysate flow rate of 500 mL/min. Ultrafiltration was
1-98 and mortality in subjects with defined cardiovascu- varied according to the actual weight gain of the patients.
lar disorders as well as in the total population. Therefore, All patients underwent electrocardiogram and echo-
proANP 1-98 may predict future cardiovascular disor- cardiography. Some patients had additional radionuclide
ders [14–18]. Successful heart transplantation may nor- ventriculography or cardiac catheterization to exclude
malize the elevated circulating concentrations of pro-
or confirm cardiac dysfunction. Cardiac dysfunction was
ANP 1-98 and proANP 31-67 [19]. Supraventricular and
defined as the presence of congestive heart failure or
ventricular arrhythmias were also associated with sig-
cardiomyopathy with significantly reduced left ventricu-nificantly increased levels of proANP 1-98 and proANP
lar ejection fraction, existence of moderate- or high-31-67, which decreased after conversion to sinus rhythm
grade valve dysfunction, or current atrial fibrillation. Dry[20]. Furthermore, the release of the whole N-terminus
body weight was assessed for each patient on the basis(proANP 1-98) and the midportion of the N-terminus
of chest x-ray and clinical observations such as peripheral(proANP 31-67) is triggered by myocardial necrosis in
edema, dyspnea, hypertension, or dialysis-associated hy-patients with acute myocardial infarction, but not in pa-
potension and/or cramps. Additional assessment of thetients with unstable angina and ischemia [21].
vena cava inferior diameter (VCID) by sonography, asNatriuretic peptides are elevated in patients with end-
described by Cheriex et al [27], was performed in thestage renal disease (ESRD) and decrease during the
majority of the patients. Therefore, the patients havedialysis session when fluid is removed [22–25]. The accu-
been considered to be on an adequate dry body weight.racy and usefulness of natriuretic peptides as biochemical
Besides normal blood pressure control (no antihyper-makers for the estimation of dry body weight in dialysis
tensive drugs), hypertension was defined as mild (onepatients have recently been investigated [25, 26], but
drug), moderate (two or three drugs), or severe (fourhave failed to be reliable. Based on these data, a re-
drugs or more). Systolic and diastolic blood pressuresevaluation of circulating proANP fragments in a large
were measured before, during, and at the end of hemodi-group of patients with ESRD seemed to be indicated.
alysis treatment. For statistical analysis, mean arterialTherefore, the present study was performed to investi-
blood pressure (MAP) was calculated. Dialysis-associ-gate the influence of periodic circulatory volume expan-
ated hypotension was defined as a drop of systolic bloodsion, as commonly found in patients with chronic renal
pressure below 100 mm Hg, and frequency was calcu-failure undergoing regular hemodialysis therapy, on
lated over the period of the last four weeks, graduatingplasma concentrations of different proANP fragments,
in no episodes or frequent episodes (three or more).with respect to the presence or absence of cardiac disor-
As a control group, 16 healthy volunteers (hospitalders. Furthermore, any potential differences between
staff) with a mean 6 SD age of 36 6 10 years (rangepatients with hypertension or those with dialysis-associ-
ated hypotension, as clinical signs for possible volume 23 to 54) were studied. No drugs were taken by these
Franz et al: ProANP peptides during hemodialysis376
volunteers except hormonal contraceptives in some fe-
males.
Analytical methods
Blood samples were obtained by puncture of blood
access after supine rest of at least 15 minutes before the
start of a regularly scheduled hemodialysis session. After
hemodialysis, blood samples were obtained from the
atrial line of the hemodialysis system immediately before
discontinuation of the extracorporeal circulation. In 30
patients, additional blood samples were taken during the
hemodialysis procedure after one, two, three, and four
hours. In controls blood was drawn from an antecubital
vein after supine rest of at least 10 minutes. All samples
Fig. 1. Plasma concentrations of different N-terminal fragments of thewere collected in chilled tubes containing ethylenedi- proatrial natriuretic peptide (proANP 1-30, proANP 31-67, and pro-
aminetetraacetic acid (EDTA) and aprotinin, immedi- ANP 1-98) in controls (j) as compared with regular hemodialysis (HD)
patients, measured before (h) and after ( ) hemodialysis treatment.ately placed on ice, and centrifuged within 10 minutes.
The fragments were determined by RIA as described in the MethodsPlasma was separated and stored at –708C until analysis. section. The graph shows the mean 6 SD (N 5 122). *P , 0.0001
Plasma concentrations of proANP 1-30 and proANP compared with controls (N 5 16).
31-67 were determined by competitive enzyme immuno-
assays (Biomedica GmbH, Vienna, Austria) [28]. The
detection limits were 2.5 and 10 pmol/L. ProANP 1-98
of the determined proANP fragments were still signifi-was measured by a noncompetitive sandwich-type immu-
cantly higher than in controls (Fig. 1).noassay using two antibodies specific for proANP 10-
19 and proANP 85-90 and synthetic proANP 1-98 as Plasma concentrations of a-ANP and cGMP
standard. The assay has a detection limit of 50 pmol/L
In patients on maintenance hemodialysis, plasma con-(Biomedica GmbH). Plasma a-ANP concentration was
centrations of a-ANP and cGMP were also markedlymeasured by a specific sandwich-type immunoradiome-
higher than in the control group. Before hemodialysis,tric assay (Shionogi & Co., LTD, Osaka, Japan) and
the plasma level (mean 6 SD) of a-ANP was 82.5 6 80
cGMP by RIA (Immunotech, Luminy, France).
pmol/L and thus 217-fold elevated as compared with
controls (0.38 6 0.27 pmol/L, P , 0.0001). PredialyticStatistical analysis
plasma concentration (mean 6 SD) of cGMP was 45.5 6
Results are given as means 6 SD. Statistical analyses 26 nmol/L and 379-fold elevated as compared with con-
were performed using the Student’s t-test of paired data trols (0.12 6 0.07 nmol/L, P , 0.0001). a-ANP and cGMP
when comparing differences between consecutive values decreased significantly during hemodialysis, but the
in the same individuals, differences between groups were postdialytic value of a-ANP (37.4 6 37.1 pmol/L) and
examined by unpaired t-tests. A simple correlation an- of cGMP (16.2 6 8.4 nmol/L) were found to be still
alysis was performed by one-way analysis of variance markedly higher than in normal persons (98-fold for
(ANOVA). A P value less than 0.05 was considered the a-ANP and 135-fold for cGMP, P , 0.0001).
level of significance.
Plasma concentrations of cGMP, a-ANP, and
proANP fragments in hemodialysis patients with
RESULTS or without cardiac dysfunction and changes during
Plasma concentrations of proANP fragments in hemodialysis treatment
hemodialysis patients versus healthy controls Table 1 demonstrates that a-ANP and proANP frag-
In healthy volunteers, the plasma concentrations of ments were found to be significantly higher in patients
proANP 1-30, proANP 31-67, and proANP 1-98 varied with cardiac dysfunction than in patients with normal
between 0.12 and 0.41 nmol/L. In hemodialysis patients, cardiac function, before as well as after hemodialysis.
predialytic levels of proANP 1-98 were 98-fold, while Plasma levels of cGMP, however, did not differ between
proANP 31-67 were 56-fold, and proANP 1-30 were 35- the two groups before hemodialysis. The relative changes
fold elevated, as compared with controls (Fig. 1). During in the concentrations of cGMP, a-ANP, and proANP
the hemodialysis session, the plasma concentrations of were less pronounced when cardiac dysfunction existed
proANP 1-98, proANP 31-67, and proANP 1-30 de- (relative decrease of cGMP 55.3 vs. 66.5%, a-ANP 52.7
vs. 56%, proANP 1-30 7.5 vs. 29.4%, proANP 31-67 12.8creased. At the end of hemodialysis, the concentrations
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Table 1. Plasma concentrations of cyclic GMP, a-ANP and levels of cGMP, a-ANP, proANP 1-30, proANP 31-67,
N-terminal fragments of the proatrial natriuretic peptide (proANP
or proANP 1-98 and interdialytic weight gain or between1-30, proANP 31-67 and proANP 1-98) in regular hemodialysis
patients with normal cardiac function (CN) as compared to the respective postdialytic plasma concentrations and
hemodialysis patients with cardiac dysfunction (CD), measured volume removal during hemodialysis (r between 0.01
before and after a regular scheduled hemodialysis session
and 0.36, P 5 NS). Also, the serial evaluation of the
CN N 5 91 CD N 5 31 Significance peptides measured in 30 patients after one, two, three,
Before hemodialysis and four hours during the hemodialysis session did not
Cyclic GMP nmol/L 43.4625.2 41.9616.4 NS show a correlation between the ultrafiltration rate and
a-ANP pmol/L 51.6628.3 122.26107.7 P,0.0001
changes of the respective plasma concentrations (r be-ProANP 1-30 nmol/L 6.863.6 13.265.6 P,0.0001
ProANP 31-67 nmol/L 8.963.7 14.063.8 P,0.0001 tween 0.02 and 0.28, P 5 NS). For changes in vascular
ProANP 1-98 nmol/L 14.169.1 31.9616.7 P,0.0001 volume, hemoconcentration as indicated by the variation
After hemodialysis
of hematocrit did not significantly change during hemo-Cyclic GMP nmol/L 14.567.5 18.766.6 P,0.01
a-ANP pmol/L 22.9618 57.7638.7 P,0.0001 dialysis when comparing predialysis and postdialysis val-
ProANP 1-30 nmol/L 4.863.6 10.765.4 P,0.0001 ues (34.5 6 4.6 vs. 35.1 6 4.4%; P 5 NS). Furthermore,
ProANP 31-67 nmol/L 7.063.7 12.264.2 P,0.0001
the VCID, determined after the hemodialysis procedure,ProANP 1-98 nmol/L 7.967.1 22.2612.8 P,0.0001
did not correlate either with the respective plasma con-Data are mean 6 SD. Abbreviations are: ANP, atrial natriuretic peptide; cyclic
GMP, cyclic 39,59 guanosine monophosphate. centrations of proANP 1-30, proANP 31-67, and pro-
ANP 1-98, or with a-ANP and cGMP (r between 0.03
and 0.25, P 5 NS).
vs. 21.3%, proANP 1-98 30.4 vs. 43.9%). Patients with Effect of hypertension and intradialytic blood pressure
or without normal cardiac function were comparable on plasma concentrations of cGMP, a-ANP, and
with respect to MAP (predialytic 98 6 14 vs. 99 6 17 proANP fragments
mm Hg; postdialytic 94 6 15 vs. 99 6 16 mm Hg; P 5 In hemodialysis patients with normal cardiac function
NS), volume removal during hemodialysis (2.4 6 1.0 vs. and normal blood pressure or mild hypertension (group A;
2.2 6 1.0 kg; P 5 NS), and dialyzer membrane material. N 5 58), MAP before hemodialysis was 94 6 15 mm Hg
The etiology of altered left ventricular hemodynamics, and thus significantly lower than in patients with moder-
such as atrial fibrillation, moderate to severe valve dys- ate or severe hypertension (group B; N 5 33; MAP 105 6
function, and congestive heart failure or cardiomyopathy 8 mm Hg, P , 0.001). Both groups were comparable
was not associated with significant differences of circulat- with respect to interdialytic weight gain (2.5 6 0.9 kg
ing a-ANP, cGMP, and proANP fragments (Table 2). vs. 2.8 6 1.1 kg, P 5 NS). At the end of hemodialysis,
MAP was comparable in both groups (92 6 17 vs. 97 6
Correlations between N-terminal proANP fragments 12 mm Hg, P 5 NS).
before and after hemodialysis treatment Table 4 demonstrates that before the hemodialysis
The plasma concentrations of proANP 1-30, proANP procedure, plasma levels of a-ANP, cGMP, and proANP
31-67, and proANP 1-98 were well correlated to each fragments were significantly higher in patients with more
other, before and after hemodialysis (Table 3). The cor- severe hypertension (group B) as compared with patients
relation was highly significant in hemodialysis patients with normotension or only mild hypertension (group A).
with normal cardiac function. Overall, there was also a After hemodialysis, proANP 31-67 remained signifi-
positive correlation between predialytic or postdialytic cantly (P , 0.02) elevated in group B. A trend for higher
concentrations of N-terminal proANP fragments and the proANP 1-98 concentrations (P , 0.08) was also ob-
corresponding levels of a-ANP [correlation coefficient served, but the levels of a-ANP, cGMP, and proANP
(r) between 0.52 and 0.62, P , 0.0001]. Plasma levels of 1-30 were not different between groups A and B
proANP fragments and cGMP were less closely corre- (Table 4).
lated or did not correlate at all (Table 3). Patients who never presented with dialysis-associated
hypotension (group I, N 5 46) did not significantly differ
Influence of the volume status on plasma from those patients with frequent episodes (group II,
concentrations of cGMP, a-ANP, and N 5 16) with respect to their plasma concentrations
proANP fragments of the determined peptides and propeptide fragments,
The interdialytic weight gain ranged between 0 and before as well as after hemodialysis (Table 5). In group
5.6 kg with a mean value 6 SD of 2.4 6 1.0 kg in patients I, MAP was significantly higher than in group II, before
with normal cardiac function, and between 0.4 and 5.0 (102 6 9 vs. 91 6 17 mm Hg, P , 0.01) as well as after
kg with a mean value of 2.2 6 1.0 kg in patients with hemodialysis treatment (99 6 11 vs. 82 6 18 mm Hg,
cardiac dysfunction (P 5 NS). In both groups, there P , 0.001).
Out of the 30 patients who underwent serial evaluationwas no significant correlation between predialytic plasma
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Table 2. Plasma concentrations of cyclic GMP, a-ANP and N-terminal fragments of the proatrial natriuretic peptide (proANP 1-30, proANP
31-67 and proANP 1-98) in regular hemodialysis patients with cardiac dysfunction
Atrial Valve Congestive heart failure/
fibrillation dysfunction cardiomyopathy
N 5 8 N 5 7 N 5 16 Significance
Before hemodialysis
Cyclic GMP nmol/L 40.0614.1 44.1626.9 41.5617.4 NS
a-ANP pmol/L 114.3653.2 120.7660.0 131.66135.1 NS
ProANP 1-30 nmol/L 13.166.5 11.965.2 14.666.3 NS
ProANP 31-67 nmol/L 14.364.0 13.263.0 14.563.4 NS
ProANP 1-98 nmol/L 29.5615.2 34.1617.1 32.1618.3 NS
After hemodialysis
Cyclic GMP nmol/L 19.269.7 18.3614.6 18.665.4 NS
a-ANP pmol/L 54.4630.6 53.3633.8 65.4641.6 NS
ProANP 1-30 nmol/L 10.664.7 10.762.2 10.866.4 NS
ProANP 31-67 nmol/L 12.264.1 12.362.4 12.164.6 NS
ProANP 1-98 nmol/L 19.8612.7 22.1610.4 24.7613.3 NS
Data are mean 6 SD. Comparisons are between patients with atrial fibrillation, valve dysfunction, and congestive heart failure or cardiomyopathy, measured
before and after a regularly scheduled hemodialysis session. NS is not significant.
Table 3. Correlation coefficient (r) of predialytic and postdialytic plasma concentrations of N-terminal proANP fragments and cyclic GMP
in regular hemodialysis patients with normal cardiac function (CN) as compared to hemodialysis patients with cardiac dysfunction (CD)
CN Significance CD Significance
Predialytic
ProANP 1-30 vs. proANP 31-67 r50.69 P,0.0001 r50.61 P,0.01
ProANP 1-30 vs. proANP 1-98 r50.70 P,0.0001 r50.52 P,0.01
ProANP 1-30 vs. cyclic GMP r50.29 P,0.01 r50.31 NS
ProANP 31-67 vs. proANP 1-98 r50.68 P,0.0001 r50.47 P,0.02
ProANP 31-67 vs. cyclic GMP r50.25 P,0.02 r50.07 NS
ProANP 1-98 vs. cyclic GMP r50.01 NS r50.26 NS
Postdialytic
ProANP 1-30 vs. proANP 31-67 r50.68 P,0.0001 r50.66 P,0.001
ProANP 1-30 vs. proANP 1-98 r50.54 P,0.0001 r50.55 P,0.01
ProANP 1-30 vs. cyclic GMP r50.21 NS r50.27 NS
ProANP 31-67 vs. proANP 1-98 r50.68 P,0.0001 r50.72 P,0.0001
ProANP 31-67 vs. cyclic GMP r50.16 NS r50.20 NS
ProANP 1-98 vs. cyclic GMP r50.24 NS r50.42 P,0.05
of proANP fragments, 6 patients had persistent intradia- there was again no significant difference in the plasma
concentrations of proANP peptides between both groups.lytic hypertension, and another 6 patients actually dis-
played a hypotensive episode. The baseline plasma con-
Effect of different dialyzer membranes on plasmacentration of proANP 1-30 was significantly higher in
concentrations of cGMP, a-ANP, andthe hypertensive patients (11.1 6 1.6 vs. 5.2 6 2.2,
proANP fragmentsmean 6 SD; P , 0.04), whereas their plasma levels of
proANP 31-67 and proANP 1-98 were comparable to The majority of patients with normal cardiac function
the other six patients with normal or low blood pressure were treated with high-flux membrane dialyzers (N 5
(proANP 31-67, 12.9 6 1.1 vs. 12.1 6 6.3; proANP 1-98, 80). The decrease of plasma concentrations of proANP
21.9 6 3.5 vs. 20.0 6 3.1; P 5 NS). After one and two 1-30, proANP 31-67, and proANP 1-98 during the hemo-
hours of hemodialysis, there was no significant difference dialysis procedure was significantly higher with the use
of the proANP peptides between the two groups. After of cellulose-triacetate dialyzers than with polysulfone di-
three hours and when the hypotensive episode occurred alyzers (Table 6). No differences were found for plasma
in the six patients, their respective plasma concentration concentrations of a-ANP or cGMP.
of proANP 31-67 was significantly lower compared with
those patients with persistent hypertension (6.2 6 2.5 vs.
DISCUSSION11.4 6 5.1 mol/L, P , 0.05). No such difference was
found for circulating proANP 1-30 (2.5 6 1.2 vs. 4.0 6 In the present study, we investigated circulating N-ter-
minal proANP peptides in 122 patients with ESRD who1.6, P 5 NS) and proANP 1-98 (18.0 6 3.1 vs. 21.5 6
1.9, P 5 NS). After four hours of hemodialysis treatment, were undergoing regular hemodialysis treatment. Anti-
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Table 6. Plasma concentrations of cyclic GMP, a-ANP andTable 4. Plasma concentrations of cyclic GMP, a-ANP and
N-terminal fragments of the proatrial natriuretic peptide (proANP N-terminal fragments of the proatrial natriuretic peptide (proANP
1-30, proANP 31-67 and proANP 1-98) in regular hemodialysis1-30, proANP 31-67 and proANP 1-98) in regular hemodialysis
patients with normal cardiac function patients with normal cardiac function
PS CTGroup A Group B
N 5 58 N 5 33 Significance N 5 51 N 5 29 Significance
Before hemodialysisBefore hemodialysis
cyclic GMP nmol/L 37.5623.8 53.2624.4 P , 0.007 Cyclic GMP nmol/L 45.2627.4 44.2627.9 NS
a-ANP pmol/L 51.6629.3 47.4629.0 NSa-ANP pmol/L 45.5629.3 60.3624.5 P , 0.025
ProANP 1-30 nmol/L 5.863.2 7.764.2 P , 0.035 ProANP 1-30 nmol/L 6.563.6 6.264.2 NS
ProANP 31-67 nmol/L 9.164.0 8.163.4 NSProANP 31-67 nmol/L 7.862.9 10.264.1 P , 0.004
ProANP 1-98 nmol/L 11.866.6 16.6611.5 P , 0.02 ProANP 1-98 nmol/L 14.169.2 13.6612.7 NS
After hemodialysisAfter hemodialysis
cyclic GMP nmol/L 13.867.9 15.366.9 NS Cyclic GMP nmol/L 16.069.9 14.266.0 NS
a-ANP pmol/L 23.1619.8 24.7622.3 NSa-ANP pmol/L 21.9619.6 24.2615.8 NS
ProANP 1-30 nmol/L 4.163.4 5.263.3 NS ProANP 1-30 nmol/L 5.163.4 2.761.6 P , 0.014
ProANP 31-67 nmol/L 7.263.3 4.462.2 P , 0.004ProANP 31-67 nmol/L 6.163.2 8.063.8 P , 0.02
ProANP 1-98 nmol/L 6.666.3 9.468.0 NS ProANP 1-98 nmol/L 9.368.0 4.163.1 P , 0.014
Data are mean 6 SD. Comparisons are between normotensive or mild hyper- Data are mean 6 SD. Comparisons are between high-flux polysulfone dialyz-
ers (PS) and high-flux cellulose triacetate dialyzers (CT) before and after atensive patients (Group A) and hemodialysis patients with moderate or severe
hypertension (Group B) before and after a regularly scheduled hemodialysis regular scheduled hemodialysis session.
session.
those hemodialysis patients with normal cardiac func-
Table 5. Plasma concentrations of cyclic GMP, a-ANP and tion. (4) Hypertension, but not dialysis-induced hypoten-N-terminal fragments of the proatrial natriuretic peptide (proANP
sion, is associated with significant differences of circulat-1-30, proANP 31-67 and proANP 1-98) in regular hemodialysis
patients with normal cardiac function ing proANP fragments. (5) Hemodialysis treatment
using cellulose-triacetate dialyzers reduced plasma levelsGroup I Group II
N 5 46 N 5 16 Significance of proANP 1-30, proANP 31-67, and proANP 1-98 more
than hemodialysis therapy using polysulfone dialyzers.Before hemodialysis
cyclic GMP nmol/L 48.2628.2 44.4619.1 NS In uremic patients, plasma concentrations of the C-
a-ANP pmol/L 55.8629.6 51.6622.2 NS terminus of the prohormone (that is, a-ANP) are deter-ProANP 1-30 nmol/L 7.664.1 5.862.5 NS
mined by the level of the intravascular filling volumeProANP 31-67 nmol/L 9.664.2 8.462.8 NS
ProANP 1-98 nmol/L 16.0611.2 12.466.8 NS and the resulting atrial distension. Elevated plasma con-
After hemodialysis centrations in patients with chronic renal failure couldcyclic GMP nmol/L 15.367.1 17.0611.2 NS
also be explained by the disappearance of the hormone’sa-ANP pmol/L 25.5619.0 24.2623.2 NS
ProANP 1-30 nmol/L 4.763.2 4.362.9 NS clearance by the kidney, either by excretion or by meta-
ProANP 31-67 nmol/L 7.564.1 6.262.9 NS bolism. On the other hand, elimination of hormonesProANP 1-98 nmol/L 9.669.2 5.664.6 NS
across dialyzers may contribute to changes in plasma
Data are mean 6 SD. Comparisons are between patients without episodes of
concentrations and symptoms occurring during hemodi-dialysis-associated hypotension (Group I) and hemodialysis patients with fre-
quent episodes (Group II), measured before and after a regular scheduled hemo- alysis treatment. The contribution of the kidney to the
dialysis session.
whole body metabolic clearance rate for a-ANP is small
(approximately 14%) so that diminished excretory func-
tion of the kidney alone cannot explain the significant
rise of plasma levels. Since only a small amount ofsera have been developed that recognize specific regions
within residues of the amino acid sequence 1-98. These a-ANP was detected in dialysis fluid [23], the elimination
by diffusion across the dialyzer membrane is negligible.antisera possess negligible cross-reactivity with the C-ter-
minal portion of the prohormone [28]. These antisera It is postulated that the increased circulating volume in
chronic renal failure stimulates a-ANP secretion andwere then used to measure the amounts of proANP 1-30,
proANP 31-67, and proANP 1-98 in plasma. The results that the decrease during hemodialysis treatment is di-
rectly correlated to fluid removal and to the loss in bodyof the study demonstrate the following: (1) N-terminal
proANP fragments (proANP 1-30, proANP 31-67, and weight. However, we could not find a direct correlation
between the amount of fluid removed during the hemodi-proANP 1-98) are highly elevated in hemodialysis pa-
tients as compared with healthy controls. (2) The relative alysis session and a-ANP plasma concentrations. Peri-
odic secretion as well as instability of the hormone maydecrease during hemodialysis is less pronounced for pro-
ANP fragments than for a-ANP and cGMP. (3) Uremic influence the analysis and thus the reproducibility.
Since other peptides of the prohormone, the wholepatients with cardiac dysfunction display significantly
higher plasma concentrations of proANP fragments than N-terminus (proANP 1-98), the midportion of the N-ter-
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minus (proANP 31-67) that is proteolytically cleaved population with normal cardiac function, and have found
that high-flux cellulose triacetate dialyzers reduced allfrom the N-terminus, as well as proANP 1-30 and pro-
ANP 79-98 have been found in the circulation of healthy proANP peptides significantly more than high-flux poly-
sulfone dialyzers (Table 6). According to their molecularsubjects and in human pathologies, their role in dialysis
patients has been investigated. The better stability of weight and size, respectively, elimination across the dia-
lyzer membrane is unlikely. We suggest that differencesN-terminal fragments of proANP than the C-terminus
(for example, a-ANP) in the plasma should be associated in membrane adsorption for proANP fragments may be
a possible explanation for the observed variations ofwith more reliable test results.
Our data showed that plasma levels of proANP 1-30, proANP peptides during hemodialysis treatment. Low-
flux dialyzer membranes were used in only some patients.proANP 31-67, and proANP 1-98 were markedly higher
in patients undergoing regular hemodialysis treatment The heterogeneity of membrane material as well as im-
portant differences in patient characteristics did not jus-than in healthy controls (Fig. 1). However, their rela-
tive increase was less pronounced than for a-ANP and tify a comparison of low-flux with high-flux membrane
dialyzers.cGMP. Overall plasma concentrations of proANP 1-30,
proANP 31-67, and proANP 1-98 decreased during he- Similar results to the study of Winters and Vesely were
obtained in some of the patients studied by our groupmodialysis (Fig. 1). It is unknown whether the kidney
clears proANP fragments. It may be that in the uremic [12]. Although the peptide levels changed during hemo-
dialysis in the vast majority of patients, in several patientsstate the kidney is responsible for a higher percentage
of metabolic clearance of proANP fragments. It may there was no decrease in peptide fragments during dial-
ysis. In patients with normal cardiac function, proANPalso be likely that nonrenal clearance of these petides
decreases in uremia and therefore contributes to the 1-30 did not decline in 25%, proANP 31-67 in 22%, and
proANP 1-98 in 10% of the patients investigated. Weincreased levels. So far, it has been demonstrated that
N-terminal proANP peptides have biological functions, have investigated various factors that might explain this
phenomenon, for example, ultrafiltration rate, type ofbut the effects of these peptides are not well character-
ized in pathophysiological situations. A recent study per- dialyzer membrane, blood pressure control, or medical
intervention during hemodialysis. However, we cannotformed by Villarreal et al indicates that proANP 31-67
has important hemodynamic and renal effects in hyper- give reasons for this observation. It is also of interest
that in the majority of these patients the plasma concen-tensive rats due to the hypotensive and natriuretic ac-
tions of the peptide [29]. It was concluded that circulating tration of only one proANP fragment did not decline,
whereas the other proANP peptides did.levels of proANP 31-67 may represent one adaptive
mechanism, which is independent of a-ANP and is in- Our study demonstrates that predialytic and postdia-
lytic plasma levels of proANP fragments correlate tovolved in the regulation of systemic hemodynamics and
renal function in hypertension [29]. Further investiga- each other (Table 3). These correlations were also sig-
nificant between plasma propeptides and a-ANP, buttions, particularly in hypertensive humans, are necessary
to give answers to this question. proANP fragments and cGMP were less closely corre-
lated or did not correlate at all. Concentrations of circu-Winters and Vesely obtained higher plasma levels of
a-ANP and proANP 31-67, whereas lower proANP 1-98 lating proANP fragments, a-ANP, and cGMP, however,
were not correlated to the extent of interdialytic weightconcentrations were found as compared with our data.
ProANP 1-30 has not been investigated by this group. gain or fluid removal during hemodialysis, even in pa-
tients with normal cardiac function. A precise serial eval-The relative decrease of a-ANP in the study of Winters
and Vesely during hemodialysis is comparable to our uation of a-ANP, cGMP, and proANP peptides together
with calculations of the individual ultrafiltration rate inresults [12]. Those authors, however, reported a signifi-
cant rise of circulating proANP 1-98 (P , 0.002) and 30 patients throughout the hemodialysis session con-
firmed our data. Also, the VCID indicating the hydrationproANP 31-67 (P , 0.003) during the hemodialysis ses-
sion. This effect was explained by the respective abilities state of patients did not correlate with the respective
plasma levels of the peptides. Therefore, factors otherof propeptides to cross the dialyzer membrane. It was
found that only 1.5% of proANP 1-98 and proANP than volume overload alone may contribute to the in-
crease of natriuretic peptides and propeptides.31-67 was cleared by the dialyzer [12]. We could not
confirm these findings, however. The differences may Recent investigations on proANP fragments in pa-
tients with altered left ventricular hemodynamics haveresult from the relative small group without information
on cardiac function of the patients studied by Winters documented elevated concentrations of circulating pro-
peptides due to increased synthesis and secretion. There-and Vesely and by differences in dialyzer membranes
used [12]. fore, we have compared hemodialysis patients displaying
normal cardiac function with those patients sufferingWe have studied the effects of different dialyzer mem-
branes on circulating proANP fragments in our patient from cardiac dysfunction. There was a significant differ-
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ence in predialytic plasma levels of a-ANP and proANP ent attempt to overcome the constriction of blood vessels
[31]. Baker et al showed a strong positive correlation offragments between these two groups of patients (Table
1). Plasma levels were much higher in both groups, either N-terminal ANP fragments with blood pressure and
heart rate [30]. Also, in pregnant women with pre-before or after hemodialysis, as compared with nondia-
lyzed patients with congestive heart failure. Azizi et al eclampsia [32] or in patients with pheochromocytomas
[33], proANP 1-98 and proANP 31-67 circulate in higherreported mean a-ANP plasma levels between 22 and 60
pmol/L and proANP 1-30 concentrations between 0.5 concentrations. Our data are in agreement with the re-
ported results. We found that severity of hypertension,and 1.9 nmol/L according to the NYHA functional classi-
fication (class I to class III) [16]. In another study by defined according to the prescribed number of antihy-
pertensive drugs, was linked to higher plasma levels ofLerman et al, mean plasma proANP 1-98 concentration
in patients with symptomless left-ventricular dysfunction proANP fragments, a-ANP, and cGMP (Table 4). The
difference, however, was statistically significant for pre-was 0.24 nmol/L, and hence much lower than in our
hemodialysis patients [14]. Thus, it is demonstrated that dialytic values only, as long as blood pressure was sig-
nificantly higher in the hypertensive group. After hemo-ESRD may have a stronger impact on elevated circulat-
ing a-ANP and proANP fragments than cardiac dysfunc- dialysis, MAP was comparable between the two groups.
Significant differences were found only for proANP 31-tion, and may be explained by either enhanced accumula-
tion, increased production, or both. 67. Thus, it is likely that the actual blood pressure caused
by fluid overload stimulates production of ANP peptidesThe hemodialysis procedure lowered plasma concen-
trations of cGMP, a-ANP, and proANP peptides less in and propeptides rather than the overall long-term effect
of hypertension.patients with cardiac dysfunction than without cardiac
dysfunction. The difference was more pronounced for In contrast, we found no significant differences be-
tween patients with frequent dialysis-induced hypoten-cGMP and proANP fragments than for a-ANP, and was
highest for proANP 1-30. Both groups of patients were sive episodes and those without (Table 5). One would
rather expect higher or lower plasma levels in these pa-comparable with respect to fluid removal and intradia-
lytic reduction of body weight, to dialyzer membrane tients than in patients without such events. Increased
plasma concentrations would explain the excessive vaso-material, and in their blood pressure control, respec-
tively. Baker et al could demonstrate that N-terminal dilatory effect, whereas low concentrations would be
indicative for reduced stimulation caused by hypoten-ANP fragments remained elevated at 60-minutes postex-
ercise, reflecting the longer half-life of the N-terminus sion. In addition, we have compared the plasma levels
of proANP fragments between patients who displayedin the circulation [30]. Thus, we suppose that the longer
half-life of proANP peptides may contribute to the dif- severe and persistent intradialytic hypertension and pa-
tients who actually had a hypotensive episode during theferences in the relative decrease during hemodialysis.
The smaller decrease of all proANP fragments in hemo- hemodialysis session. Although only six patients of each
group were studied, data on serial measurements of thedialysis patients with cardiac dysfunction, however, attri-
butes rather to cardiac factors. Particularly, mean values circulating peptides, and their changes during hemodial-
ysis exist. Persistent intradialytic hypertension was notof proANP 1-30 decreased during hemodialysis by 7.5%
only when cardiac hemodynamics are altered. Etiology associated with significantly different variations of pro-
ANP fragments except baseline values obtained beforeof cardiac dysfunction, however, such as congestive heart
failure, cardiomyopathy, valve dysfunction, or atrial fi- hemodialysis when compared with hypotensive patients.
The higher decrease of proANP 31-67 observed in associ-brillation, had no influence on the plasma levels of the
respective peptides (Table 2). We speculate that plasma ation with a dialysis-associated hypotensive episode may
reflect its possible role in the regulation of systemic he-levels of proANP 1-30 might be predicative for cardio-
vascular disorders and may probably reflect cardiac mor- modynamics, as recently demonstrated in a study by
Villarreal et al in the hypertensive rat [29]. However,bidity and mortality as a prognostic factor. In hemodialy-
sis patients with moderate or severe hypertension but yet this hypothesis must be handled with caution because of
the small number of patients investigated.normal cardiac function (discussed later in this article),
proANP 31-67 remained elevated compared with nor- In summary, the results of our study demonstrate that
plasma concentrations of N-terminal proANP fragmentsmotensive or only mild hypertensive patients (Table 4).
Increased cardiac stress caused by hypertension might (proANP 1-30, proANP 31-67, and proANP 1-98) are
markedly elevated in patients undergoing regular hemo-be a possible explanation.
Hypertension is frequently associated with elevated dialysis compared with healthy controls. The overall de-
crease of the proANP fragments during hemodialysisproANP and a-ANP concentrations. McMurray and
Vesely demonstrated that circulating concentrations of was more pronounced for proANP 1-98 than for proANP
1-30 and proANP 31-67. However, the extent of fluidproANP 1-30, proANP 31-67, proANP 79-98, and a-ANP
increase in patients with high blood pressure in an appar- removal and intradialytic body weight reduction did not
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